Phathom Pharmaceuticals, Inc. (PHAT) Financials

PHAT Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 305.1 million 642.1 million
Dec. 31, 2025 259.1 million 697.3 million
Sept. 30, 2025 240.3 million 662.8 million
June 30, 2025 250.2 million 656.1 million

PHAT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -15.6 million 5.5 million
Dec. 31, 2025 -4.9 million 5.6 million
Sept. 30, 2025 -14.1 million 9.3 million
June 30, 2025 -62.7 million 8.3 million

PHAT Net Income

No data available :(

PHAT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 180.9 million 2.0 million 2.6 million
Dec. 31, 2025 130.0 million 2.1 million 2.7 million
Sept. 30, 2025 135.2 million 2.1 million 2.7 million
June 30, 2025 149.6 million 552.1 million 827000

PHAT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 82.1 million
Dec. 31, 2025 73.8 million
Sept. 30, 2025 73.4 million
June 30, 2025 72.5 million

PHAT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 61000 7.8 million 54.0 million -
Dec. 31, 2025 115000 7.5 million 48.4 million -
Sept. 30, 2025 27000 7.0 million 51.6 million -
June 30, 2025 97000 9.1 million 85.3 million -

PHAT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 58.3 million 12.0 million
Dec. 31, 2025 57.6 million 7.6 million
Sept. 30, 2025 49.5 million 6.2 million
June 30, 2025 39.5 million 5.0 million

PHAT

Price: $10.94

52 week price:
7.61
18.31

Earnings Per Share: -2.09 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 521200

Market Capitalization: 893.3 million

Links: